Cargando…

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)

BACKGROUND: Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma (uLMS) have HRD, including 7.5%–1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asano, Hiroshi, Oda, Katsutoshi, Yoshihara, Kosuke, Ito, Yoichi M, Matsumura, Noriomi, Shimada, Muneaki, Watari, Hidemichi, Enomoto, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250862/ https://www.ncbi.nlm.nih.gov/pubmed/35557035 http://dx.doi.org/10.3802/jgo.2022.33.e55

Ejemplares similares

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
por: Yoshihara, Kosuke, et al.
Publicado: (2023)

An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group
por: Shigeta, Shogo, et al.
Publicado: (2023)

Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey
por: Asai-Sato, Mikiko, et al.
Publicado: (2022)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO)
por: Yoshihara, Kosuke, et al.
Publicado: (2019)

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
por: Shimada, Muneaki, et al.
Publicado: (2023)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
por: Badiner, Nora, et al.
Publicado: (2023)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer
por: Oda, Katsutoshi, et al.
Publicado: (2022)

The 1st annual meeting of the East Asian Gynecologic Oncology Trial Group (EAGOT)
por: Yoshihara, Kosuke, et al.
Publicado: (2023)

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

ASGO 2nd International Workshop on Gynecologic Oncology
por: Matsumura, Noriomi, et al.
Publicado: (2013)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
por: Kondo, Eiji, et al.
Publicado: (2020)

Niraparib for ovarian cancer
Publicado: (2021)

2052. Performance of the Biofire Filmarray Meningitis/Encephalitis Panel in Cryptococcal Meningitis Diagnosis
por: Walker, Morgan, et al.
Publicado: (2018)

PReS-FINAL-2052: Costs of biologics in juvenile idiopathic arthritis: past, present and future
por: Prince, FH, et al.
Publicado: (2013)

Polymorphisms in lncRNA MIR2052HG and susceptibility to breast cancer in Chinese population
por: Yang, Hui, et al.
Publicado: (2021)

PB2052: THE HEMATOLOGICAL SIDE OF TNFRSF13B/TACI: A MONOCENTRIC EXPERIENCE
por: Beccaria, Andrea, et al.
Publicado: (2023)

The Expression, Functions and Mechanisms of Circular RNAs in Gynecological Cancers
por: Dong, Peixin, et al.
Publicado: (2020)

Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
por: Okamoto, Aikou, et al.
Publicado: (2020)

Food allergy and anaphylaxis – 2052. Vitamin D insufficiency is associated with challenge-proven food allergy in infants
por: Allen, Katie, et al.
Publicado: (2013)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

Initiatives and achievements of the Japanese Society of Obstetrics and Gynecology, Obstetrics and Gynecology MIRAI Committee 2020
por: Komatsu, Hiroaki, et al.
Publicado: (2021)

Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
por: Kobayashi, Yusuke, et al.
Publicado: (2022)

Reconsideration of Sharp Dissection in Gynecological Surgery
por: Tanase, Yasuhito, et al.
Publicado: (2023)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

Growth on Chitin Impacts the Transcriptome and Metabolite Profiles of Antibiotic-Producing Vibrio coralliilyticus S2052 and Photobacterium galatheae S2753
por: Giubergia, Sonia, et al.
Publicado: (2017)

2052: Empirical assessment of a theatrical performance on attitudes and behavior intentions toward research: The informed consent play
por: Rothwell, Erin, et al.
Publicado: (2018)

2052. Characterizing Nursing and Provider Social Networks to Develop an Instrument to Improve Antibiotic Stewardship Efforts in Nursing Homes
por: Ewers, Tola, et al.
Publicado: (2019)

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
por: Sisay, Mekonnen, et al.
Publicado: (2017)

Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
por: Asano, Hiroshi, et al.
Publicado: (2022)

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
por: Masuda, Norikazu, et al.
Publicado: (2021)

Palliative Care for Patients with Gynecologic Cancer in Japan: A Japan Society of Gynecologic Palliative Medicine (JSGPM) Survey
por: Futagami, Masayuki, et al.
Publicado: (2016)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
por: Banerjee, Susana, et al.
Publicado: (2021)

Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic
por: Matsuo, Koji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_be8dcnj2dfg5velfrqqm189pmq